Current Pipeline
COMPOUND (TARGET)
INDICATION(S)
DISCOVERY
IND ENABLING
PHASE I
PHASE II
PHASE III
NS-041
(KCNQ2/3 activator)
Focal onset seizure
Major depressive disorder
Pain
NS-136
(mAChR4 PAM)
Schizophrenia
Psychosis in Alzheimer's disease
NS-015
(Neuroplasticity)
NS-031
(NMDAR)
NS-050
(Neuroinflammation)
Treatment-resistant depression
Treatment-resistant depression
Alzheimer's disease
Parkinson’s disease
Clinical Trials
COMPOUND
INDICATION
STAGE
STUDY DESCRIPTION
STATUS
NS-136
Schizophrenia
Psychosis in
Alzheimer's disease
Phase I
A Phase 1, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and PK of Single and Multiple Ascending Oral Doses and Food Effect of NS-136 in Healthy Subjects
View StudyRecruiting
NS-041
Focal onset seizure
Major depressive disorder
Pain
Phase I
A Phase 1, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and PK of Single and Multiple Ascending Oral Doses and Food Effect of NS-041 in Healthy Subjects
View StudyRecruiting
Publications
